Irinotecan hydrochloride
ONIVYDE is a prescription injectable drug containing irinotecan hydrochloride, a topoisomerase inhibitor used intravenously to treat certain cancers. It comes as a liposomal powder for solution, manufactured by Ipsen Biopharmaceuticals, Inc., and approved under NDA207793. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | ONIVYDE is a prescription injectable drug containing irinotecan hydrochloride, a topoisomerase inhibitor used intravenously to treat certain cancers. It comes as a liposomal powder for solution, manufactured by Ipsen Biopharmaceuticals, Inc., and approved under NDA207793. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Irinotecan hydrochloride",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Irinotecan hydrochloride — ANDA 077915 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077915"
}
]
|
| identifier | ANDA077915 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-manufacturers",
"medications",
"prescription-drugs",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Irinotecan hydrochloride |
